Tela Bio Exceeds $20M Revenue in Q2 2025, Reiterates $85M-$88M 2025 Target Amid International Expansion
ByAinvest
Monday, Aug 11, 2025 7:08 pm ET1min read
TELA--
The Q2 2025 revenue increased by 26% year-over-year, reaching $20.2 million. Revenue from OviTex grew by 12%, while OviTex PRS revenue surged by 53%. Gross margin improved to 69.8% from 68.8% in the prior year period. The company ended the quarter with $35 million in cash and cash equivalents [2].
CEO Antony Koblish highlighted the strong performance, stating, "Q2 2025 was the first quarter to exceed $20 million in revenue, stemming from the highest global unit sales in the quarter across all product categories." The company's international sales grew by 25% over Q2 last year, with European sales contributing significantly to this growth [2].
TELA Bio has expanded its European market presence with a new product launch and secured a 4-year framework agreement with the National Health Service (NHS) in England. The company has also appointed Jeff Blizzard as President, who brings extensive European market experience and a track record of delivering predictable growth [2].
The company's focus on enhanced territory management and a patient-centric commercial strategy is expected to drive future growth. TELA Bio aims to achieve its full-year 2025 guidance of $85 million to $88 million, representing a 23% to 27% year-over-year growth [2].
Analysts maintain a neutral to slightly positive tone, with the current average analyst rating on the shares being "buy." The average consensus recommendation for the medical equipment, supplies & distribution peer group is also "buy" [1].
References:
[1] https://www.tradingview.com/news/reuters.com,2025:newsml_PLXBE3528:0-tela-bio-misses-q2-revenue-estimates/
[2] https://seekingalpha.com/news/4483591-tela-bio-reiterates-85m-88m-2025-revenue-target-as-international-expansion-accelerates
Tela Bio reiterated its 2025 revenue target of $85M-$88M, citing acceleration in international expansion. Q2 2025 saw the first quarter to exceed $20M in revenue, with the highest global unit sales across all products.
TELA Bio, Inc. (TELA) has reiterated its 2025 revenue target of $85 million to $88 million, reflecting acceleration in international expansion. The company reported its second quarter (Q2) 2025 results, with revenue exceeding $20 million for the first time, driven by the highest global unit sales across all products [1].The Q2 2025 revenue increased by 26% year-over-year, reaching $20.2 million. Revenue from OviTex grew by 12%, while OviTex PRS revenue surged by 53%. Gross margin improved to 69.8% from 68.8% in the prior year period. The company ended the quarter with $35 million in cash and cash equivalents [2].
CEO Antony Koblish highlighted the strong performance, stating, "Q2 2025 was the first quarter to exceed $20 million in revenue, stemming from the highest global unit sales in the quarter across all product categories." The company's international sales grew by 25% over Q2 last year, with European sales contributing significantly to this growth [2].
TELA Bio has expanded its European market presence with a new product launch and secured a 4-year framework agreement with the National Health Service (NHS) in England. The company has also appointed Jeff Blizzard as President, who brings extensive European market experience and a track record of delivering predictable growth [2].
The company's focus on enhanced territory management and a patient-centric commercial strategy is expected to drive future growth. TELA Bio aims to achieve its full-year 2025 guidance of $85 million to $88 million, representing a 23% to 27% year-over-year growth [2].
Analysts maintain a neutral to slightly positive tone, with the current average analyst rating on the shares being "buy." The average consensus recommendation for the medical equipment, supplies & distribution peer group is also "buy" [1].
References:
[1] https://www.tradingview.com/news/reuters.com,2025:newsml_PLXBE3528:0-tela-bio-misses-q2-revenue-estimates/
[2] https://seekingalpha.com/news/4483591-tela-bio-reiterates-85m-88m-2025-revenue-target-as-international-expansion-accelerates
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
Comments
No comments yet